New cell therapy takes aim at Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests a new cell therapy (NW-301V or NW-301D) in 9 adults with advanced solid tumors that have specific KRAS mutations (G12V or G12D) and no standard treatment options. Participants receive their own immune cells that have been genetically engineered to rec…
Phase: PHASE1 • Sponsor: TingBo Liang • Aim: Disease control
Last updated May 06, 2026 16:13 UTC